Physician profile
Christopher Simon
NPI 1962481440
$16,500.61
in general payments reported to CMS, 2019-2025
63 companies · $3,813 in 2025
The $3,813 reported for 2025 was more than what 82% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $576 · 2020: $921 · 2021: $1,817 · 2022: $2,008 · 2023: $3,190 · 2024: $4,175 · 2025: $3,813.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,043.82 |
| Education | $135.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,868.38 | 2021-2025 | Ubrelvy, Botox, Duopa |
| Teva Pharmaceuticals USA, INC. | $1,460.83 | 2019-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Supernus Pharmaceuticals, INC. | $1,411.27 | 2019-2024 | Qelbree |
| Biogen, INC. | $1,190.04 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Novartis Pharmaceuticals Corporation | $1,169.55 | 2019-2025 | |
| Lilly USA, LLC | $791.88 | 2019-2025 | Emgality, Amyvid, Reyvow |
| Mdd US Operations, LLC | $725.35 | 2023-2025 | Apokyn, Gocovri, Qelbree |
| Sk Life Science, INC. | $532.60 | 2020-2025 | Xcopri |
| Genentech USA, INC. | $385.93 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Allergan, INC. | $343.53 | 2019-2022 | |
| Catalyst Pharmaceuticals, INC. | $330.25 | 2021-2025 | Fycompa |
| Pfizer INC. | $327.68 | 2023-2025 | |
| Kyowa Kirin, INC. | $292.63 | 2020-2025 | Nourianz |
| Amneal Pharmaceuticals LLC | $247.87 | 2019-2025 | Rytary, Crexont, Ongentys 50mg Capsules 30 |
| Celgene Corporation | $203.19 | 2020-2025 | Zeposia |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Simon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.